[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intrahepatic-bile-duct-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intrahepatic-bile-duct-carcinoma":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,60],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100648174","inter-individual-tumor-heterogeneity-on-3d-mre-for-predicting-response-to-conversion-therapy-in-liver-cancer-100648174",false,"NCT07716345","Inter-Individual Tumor Heterogeneity on 3D-MRE for Predicting Response to Conversion Therapy in Liver Cancer","A Prospective Study on Inter-Individual Tumor Heterogeneity Assessed by Three-Dimensional Magnetic Resonance Elastography for Predicting Response to Conversion Therapy in Patients With Liver Cancer","Inclusion Criteria:\n\n* Age 18-75 years\n* Pathologically or radiologically confirmed diagnosis of initially unresectable liver cancer (hepatocellular carcinoma, intrahepatic cholangiocarcinoma, or liver metastasis)\n* Planned to receive conversion therapy with the intent of achieving surgical resectability\n* Child-Pugh class A or B liver function (for patients with primary liver cancer)\n* ECOG performance status 0-1\n* At least one measurable lesion per RECIST 1.1\n* Able to undergo 3D-MRE examination prior to conversion therapy\n* Provision of signed and dated informed consent\n\nExclusion Criteria:\n\n* Contraindication to MRI\n* Child-Pugh class C liver function (for patients with primary liver cancer)\n* Uncontrolled ascites, hepatic encephalopathy, or variceal bleeding within 3 months prior to enrollment\n* Other concurrent active malignancy\n* Severe comorbidities precluding conversion therapy or surgery\n* Pregnant or breastfeeding women\n* Anticipated poor compliance with repeated MRE examinations or follow-up","ALL","18 Years","75 Years",{"count":20,"type":21},100,"ESTIMATED","OBSERVATIONAL","How to predict which patients with initially unresectable liver cancer are more likely to respond to conversion therapy remains an important unresolved problem in guiding treatment strategy and surgical timing. Substantial variation exists among patients in their tumor response to the same conversion therapy regimen, and current pretreatment imaging assessment does not adequately capture this inter-individual variability. We hypothesize that baseline tumor viscoelastic parameters measured by three-dimensional magnetic resonance elastography (3D-MRE) differ substantially across patients, and that this inter-individual heterogeneity may be associated with differential response to conversion therapy. This study aims to prospectively evaluate the association between baseline 3D-MRE-derived tumor viscoelastic parameters and pathological response as well as surgical conversion outcomes across patients with liver cancer receiving conversion therapy.",[25,26,27],"Hepato Cellular Carcinoma","Intrahepatic Bile Duct Carcinoma","Metastatic Hepatocellular Carcinoma","NOT_YET_RECRUITING","2026-07-20",{"date":31,"type":32},"2026-07-21","ACTUAL",{"date":34,"type":21},"2026-10-01",{"date":36,"type":21},"2030-10-01",{"name":38,"class":39},"Second Affiliated Hospital of Xi'an Jiaotong University","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":4},"100647270","peritumoral-mre-stiffness-for-predicting-resection-margin-status-and-recurrence-in-liver-cancer-100647270","NCT07704216","Peritumoral MRE Stiffness for Predicting Resection Margin Status and Recurrence in Liver Cancer","A Prospective Study on the Association Between Peritumoral Elasticity Measured by Three-Dimensional Magnetic Resonance Elastography and Pathological Resection Margin Status and Postoperative Recurrence in Patients With Liver Cancer","Inclusion Criteria:\n\n* Age 18-80 years\n* Pathologically confirmed diagnosis of hepatocellular carcinoma, intrahepatic cholangiocarcinoma, or liver metastasis (e.g., from colorectal cancer)\n* Underwent curative-intent hepatectomy with available postoperative pathological resection margin assessment\n* Child-Pugh class A or B liver function (for patients with primary liver cancer)\n* Able to undergo 3D-MRE examination at postoperative day 7-14\n* Provision of signed and dated informed consent\n\nExclusion Criteria:\n\n* Contraindication to MRI (e.g., non-MRI-compatible implants, severe claustrophobia)\n* Palliative or non-curative surgery (R2 resection)\n* Presence of unresectable extrahepatic disease at the time of surgery\n* Reoperation or unplanned return to surgery within 14 days after the initial hepatectomy\n* Severe postoperative complications precluding MRI examination at postoperative day 7-14 (e.g., unstable vital signs, need for intensive care)\n* Death within 14 days after surgery from non-tumor-related causes\n* Prior history of liver resection or liver transplantation\n* Pregnant or breastfeeding women\n* Anticipated poor compliance with postoperative MRE examination or follow-up","80 Years",{"count":49,"type":21},150,"Microscopic residual tumor at the resection margin is a critical risk factor for recurrence in patients undergoing hepatectomy for liver cancer, yet current detection relies solely on postoperative pathological examination of the resected specimen, which reflects only the removed tissue rather than the actual remnant liver in the patient. How to non-invasively detect residual tumor at the resection margin of the remnant liver after surgery remains an important unresolved problem in the surgical management of liver cancer. We hypothesize that tissue stiffness at the resection margin of the remnant liver, measured by postoperative three-dimensional magnetic resonance elastography (3D-MRE), may reflect microscopic residual tumor and may therefore correlate with pathological resection margin status and be predictive of postoperative tumor recurrence. This study aims to prospectively evaluate the diagnostic performance of postoperative 3D-MRE in detecting residual tumor at the resection margin, using pathological resection margin status as the reference standard, and to further assess its value in predicting tumor recurrence in patients undergoing hepatectomy for liver cancer.",[25,26,27],"2026-07-10",{"date":54,"type":32},"2026-07-15",{"date":56,"type":21},"2026-08-01",{"date":58,"type":21},"2031-10-01",{"name":38,"class":39},{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":68,"targetDuration":4,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":78,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":98},"100584340","phase-2-additional-chemotherapy-administered-directly-into-the-liver-using-a-chemo-pump-in-patients-with-bile-duct-cancer-inside-the-liver-treatable-by-surgery-100584340","NCT06888063","Additional Chemotherapy Administered Directly Into the Liver Using a Chemo Pump in Patients With Bile Duct Cancer Inside the Liver Treatable by Surgery","Preventing Liver Recurrence After Partial Hepatectomy for Intrahepatic Cholangiocarcinoma Using Adjuvant Hepatic Arterial Infusion Pump Chemotherapy - PUMP IV Trial","PUMP IV","Inclusion Criteria:\n\n* 18 years or older\n* ECOG or WHO performance status 0 or 1\n* Diagnosis of resectable iCCA on imaging. No histological confirmation is needed before surgery, according to standard of care.\n* Patient is able to undergo a laparotomy.\n* Positioning of a catheter for HAIP chemotherapy is technically feasible based on a CT-scan with early arterial phase with 1mm cuts. The default site for the catheter insertion is the GDA. Accessory or aberrant hepatic arteries are no contraindication for catheter placement.\n* Adequate bone marrow, liver, and renal function before inclusion (values may be max. 30 days old)\n* Absolute neutrophil count (ANC) ≥ 1.5 x 10\\^ 9\u002FL\n* White blood cell count (WBC) ≥ 2.5 x 10\\^9\u002FL\n* Platelets ≥ 100 x 10\\^9\u002FL\n* Glomerular filtration rate (GFR) ≥ 30 ml\u002Fmin\n* Haemoglobin (Hb) ≥ 5.5 mmol\u002FL\n* Total bilirubin ≤ 25 µmol\u002FL\n* Written informed consent must be given according to ICH\u002Fgood clinical practice (GCP), and national\u002Flocal regulations.\n\nExclusion Criteria:\n\n* Presence of extrahepatic disease at the time of first presentation. Patients with locoregional lymph node disease or with small (≤ 1 cm) extrahepatic lesions that are too small to characterize or biopsy are eligible.\n* Second primary malignancy, except for adequately treated non-melanoma skin cancer, or other malignancy treated at least 3 years previously without evidence of recurrence or with a life expectancy longer than 5 years.\n* Known homozygous dihydropyrimidine dehydrogenase (DPYD) deficiency\n* Prior hepatic radiation, ablation, or resection for iCCA.\n* Clinical evidence of portal hypertension (ascites, gastroesophageal varices, or portal vein thrombosis). Some postoperative ascites is allowed.\n* (Partial) portal vein thrombosis in future liver remnant.\n* Pregnant or lactating women.\n* History of psychiatric disability judged by the investigator to be clinically significant, precluding informed consent or interfering with compliance for HAIP chemotherapy.\n* Serious concomitant systemic disorders that would compromise the safety of the patient or his\u002Fher ability to complete the study, at the discretion of the investigator.\n* Organ allografts requiring immunosuppressive therapy.\n* Serious infections (uncontrolled or requiring treatment).\n* Participation in another interventional study for iCCA with survival as outcome.\n* Participation in another prospective study with an interventional medical product.\n* Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial",{"count":69,"type":21},40,"INTERVENTIONAL",[72],"PHASE2","The goal of this clinical trial is to learn if additional chemotherapy by means of a chemo pump can prevent return of disease in adult patients with bile duct cancer in the liver that can be treated with surgery. The main questions it aims to answer are:\n\n* Does addition of chemotherapy by means of a chemo pump lead to less return of disease within the liver two years after surgery?\n* Does addition of chemotherapy by means of a chemo pump lead to longer survival of patients?\n* Does addition of chemotherapy by means of a chemo pump lead to an increase in quality of life?\n\nParticipants will receive an implanted chemo pump, through which additional chemotherapy will be given to the liver in addition to surgery.",[75,76,26,77],"Intrahepatic Bile Duct Cancer","Intrahepatic Cholangiocarcinoma (Icc)","Intrahepatic Cholangiocarcinoma",[79,66,80,81,82,83,84,85,86,87],"PUMP","Hepatic Arterial Infusion Chemotherapy","Hepatic Arterial Infusion Pump chemotherapy","HAIP","HAIC","Intrahepatic cholangiocarcinoma","iCCA","Floxuridin","Chemopump","RECRUITING","2025-03-14",{"date":91,"type":32},"2025-03-21",{"date":93,"type":32},"2024-11-20",{"date":95,"type":21},"2031-09",{"name":97,"class":39},"Erasmus Medical Center",1]